EGFR and non-small cell lung carcinoma: In advanced NSCLC, TKI-resistant RB1-inactivated/EGFR-mutated adenocarcinoma clones have been found to transdifferentiate into small-cell lung cancer (SCLC) and become more responsive to chemotherapy37,38.